Novocure Q3 net loss narrows 72% to USD 10.44 million

PUBT · 4d ago
Novocure Q3 net loss narrows 72% to USD 10.44 million
  • Novocure’s third-quarter 2026 net loss narrowed 72% year over year to $10.44 million.
  • Net revenues rose 16% year over year to $193.4 million, driven by 19% growth in global active patients.
  • Optune Pax secured Japanese approval in October for adults with unresectable locally advanced pancreatic cancer, alongside gemcitabine and nab-paclitaxel.
  • Full-year 2026 net revenues guidance increased to $736 million–$743 million from $710 million–$725 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610290700BIZWIRE_USPR_____20261029_BW363518) on October 29, 2026, and is solely responsible for the information contained therein.